Ononétine
Aller à la navigation
Aller à la recherche
Nom de la substance
Ononétine
Famille moléculaire
Stilbénoïde (1-(2,4-Dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone) PubChem (deoxybenzoin, désoxybenzoïne)
Source végétale
Propriétés
- Antalgique [1], inhibiteur puissant et sélectif du canal TRPM3 (melastatin-related transient receptor potential) [2], un canal cationique perméable au calcium qui joue un rôle dans la perception exagérée de la douleur [3], [4], activité équivalente à celle de l'aspirine [5] et anti-inflammatoire
- Activité œstrogénique [6]
Effet thérapeutique
- Effet potentiel dans le syndrome de fatigue chronique ou encéphalomyélite myalgique [7], [8], [9] et le syndrome post-Covid, qui partageraient une pathogénie commune (?) [10], [11]
Effets indésirables
Bibliographie
- ↑ Abbas, M., & Jaffal, S. M. (2019). Antinociceptive action of Ononis spinosa leaf extract in mouse pain models. Acta Poloniae Pharmaceutica-Drug Research, 76(2), 299-304.
- ↑ Cabanas H, Muraki K, Balinas C, Eaton-Fitch N, Staines D, Marshall-Gradisnik S. Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients. Mol Med. 2019 Apr 23;25(1):14. doi: 10.1186/s10020-019-0083-4. PMID 31014226; PMCID: PMC6480905.
- ↑ Straub, I., Mohr, F., Stab, J., Konrad, M., Philipp, S. E., Oberwinkler, J., & Schaefer, M. (2013). Citrus fruit and fabacea secondary metabolites potently and selectively block TRPM3. British journal of pharmacology, 168(8), 1835–1850. https://doi.org/10.1111/bph.12076 PMID 23190005
- ↑ Isabelle Straub, Ute Krügel, Florian Mohr, Jens Teichert, Oleksandr Rizun, Maik Konrad, Johannes Oberwinkler, Michael Schaefer. Flavanones That Selectively Inhibit TRPM3 Attenuate Thermal Nociception In Vivo. Molecular Pharmacology November 2013, 84 (5) 736-750. DOI: https://doi.org/10.1124/mol.113.086843
- ↑ Yilmaz BS, Ozbek H, Citoğlu GS, Uğraş S, Bayram I, Erdoğan E. Analgesic and hepatotoxic effects of Ononis spinosa L. Phytother Res. 2006 Jun;20(6):500-3. PMID 16619345
- ↑ Fokialakis, Nikolas & Lambrinidis, George & Mitsiou, Dimitra & Aligiannis, Nektarios & Mitakou, Sofia & Skaltsounis, Alexios-Leandros & Pratsinis, Harris & Mikros, Emmanuel & Alexis, Michael. (2004). A new class of phytoestrogens: Evaluation of the estrogenic activity of deoxybenzoins. Chemistry & biology. 11. 397-406. 10.1016/j.chembiol.2004.02.014.
- ↑ Cabanas H, Muraki K, Eaton N, Balinas C, Staines D, Marshall-Gradisnik S. Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. Mol Med. 2018 Aug 14;24(1):44. doi: 10.1186/s10020-018-0046-1. PMID 30134818; PMCID: PMC6092868.
- ↑ Eaton-Fitch N, Cabanas H, du Preez S, Staines D, Marshall-Gradisnik S. The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients. J Transl Med. 2021 Jul 15;19(1):306. doi: 10.1186/s12967-021-02974-4. PMID 34266470; PMCID: PMC8281618.
- ↑ Sasso EM, Muraki K, Eaton-Fitch N, Smith P, Lesslar OL, Deed G, Marshall-Gradisnik S. Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients. Mol Med. 2022 Aug 19;28(1):98. doi: 10.1186/s10020-022-00528-y. PMID 35986236; PMCID: PMC9388968.
- ↑ Wong TL, Weitzer DJ. Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and Symptomatology. Medicina (Kaunas). 2021 Apr 26;57(5):418. doi: 10.3390/medicina57050418. PMID 33925784; PMCID: PMC8145228.
- ↑ Campen CLMCV, Rowe PC, Visser FC. Orthostatic Symptoms and Reductions in Cerebral Blood Flow in Long-Haul COVID-19 Patients: Similarities with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Medicina (Kaunas). 2021 Dec 24;58(1):28. doi: 10.3390/medicina58010028. PMID 35056336; PMCID: PMC8778312.